Interleukin 6 blockade: Tocilizumab in psoriatic arthritis

Journal of Rheumatology

Volumn 39, Issue SUPPL. 89, 2012, Pages 97-99

  Atzeni, Fabiola ^a,b   Ventura, Donatella ^b   Batticciotto, Alberto ^b   Boccassini, Laura ^b   Sarzi Puttini, Piercarlo ^b  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Inflammatory disease; Interleukin 6; Psoriasis; Psoriatic arthritis; Tocilizumab

Indexed keywords

ALEFACEPT; CYCLOSPORIN A; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INTERLEUKIN 1; INTERLEUKIN 17; INTERLEUKIN 1ALPHA; INTERLEUKIN 23; INTERLEUKIN 6; LEFLUNOMIDE; METHOTREXATE; STAT3 PROTEIN; TOCILIZUMAB; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR INHIBITOR; ANTIINFLAMMATORY AGENT; AUTACOID; IL6 PROTEIN, HUMAN; MONOCLONAL ANTIBODY;

ANKYLOSING SPONDYLITIS; B LYMPHOCYTE; CELL DIFFERENTIATION; CONFERENCE PAPER; CYTOKINE PRODUCTION; DISEASE ACTIVITY; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; EFFECTOR CELL; HELPER CELL; HUMAN; HYPERTENSION; INFECTION; KERATINOCYTE; KIDNEY FAILURE; NEUTROPHIL COUNT; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PSORIASIS; PSORIATIC ARTHRITIS; REGULATORY T LYMPHOCYTE; RISK FACTOR; SIDE EFFECT; SKIN DISEASE; T LYMPHOCYTE ACTIVATION; TUBERCULOSIS; ANIMAL; ARTICLE; DRUG ANTAGONISM; DRUG EFFECT; HOSPITALIZATION; IMMUNOLOGY; JOINT; METABOLISM; PATHOLOGY;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; ARTHRITIS, PSORIATIC; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-6; JOINTS; SEVERITY OF ILLNESS INDEX;

EID: 84864404652     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.120256     Document Type: Conference Paper

References (16)

1. Mease PJ. Psoriatic arthritis: update on pathophysiology, assessment and management. Ann Rheum Dis 2011;70 Suppl 1:i77-84.
2. Chandran V, Raychaudhuri SP. Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis. J Autoimmun 2010;34:J314-21.
3. Mease PJ. Psoriatic arthritis - treatment update. Bull NYU Hosp Jt Dis 2011;69:243-9.
4. van Kuijk AW, Tak PP. Synovitis in psoriatic arthritis: immunohistochemistry, comparisons with rheumatoid arthritis, and effects of therapy. Curr Rheumatol Rep 2011;13:353-9.
5. Choy E. T cells in psoriatic arthritis. Curr Rheumatol Rep 2007;9:437-41. (Pubitemid 350305199)
6. Mease P, Genovese MC, Gladstein G, Kivitz AJ, Ritchlin C, Tak PP, et al. Abatacept in the treatment of patients with psoriatic arthritis: results of a double-blind, randomized, placebo-controlled phase II trial. Arthritis Rheum 2011;63:939-48.
7. Grossman RM, Krueger J, Yourish D, Granelli-Piperno A, Murphy DP, May LT, et al. Interleukin 6 is expressed in high levels in psoriatic skin and stimulates proliferation of cultured human keratinocytes. Proc Natl Acad Sci U S A 1989;86:6367-71. (Pubitemid 19210653)
8. Goodman WA, Levine AD, Massari JV, Sugiyama H, McCormick TS, Cooper KD. IL-6 signaling in psoriasis prevents immune suppression by regulatory T cells. J Immunol 2009;183:3170-6.
9. Atzeni F, Sarzi-Puttini P, Vena G. Resistant cases of psoriatic arthritis: how to manage them. J Rheumatol 2009;83:S73-5.
10. Kingsley GH, Kowalczyk A, Taylor H, Ibrahim F, Packham JC, McHugh NJ, et al. Methotrexate is not disease modifying in psoriatic arthritis: the MIPA trial. Arthritis Rheum 2010;62 Suppl:S277.
11. Atzeni F, Boccassini L, Antivalle M, Salaffi F, Sarzi-Puttini P. Etanercept plus cyclosporine versus etanercept plus methotrexate for maintaining clinical control over psoriatic arthritis: a randomised pilot study. Ann Rheum Dis 2011;70:712-4.
12. Goedkoop AY, Kraan MC, Teunissen MB, Picavet DI, de Rie MA, Bos JD, et al. Early effects of tumour necrosis factor alpha blockade on skin and synovial tissue in patients with active psoriasis and psoriatic arthritis. Ann Rheum Dis 2004;63:769-73. (Pubitemid 38850446)
13. Tak PP, Kalden JR. Advances in rheumatology: new targeted therapeutics. Arthritis Res Ther 2011;13 Suppl 1:S5.
14. Ogata A, Umegaki N, Katavama I, Kumanogoh A, Tanaka T. Psoriatic arthritis in two patients with an inadequate response to treatment with tocilizumab. Joint Bone Spine 2012;79:85-7.
15. Dayer JM, Choy E. Therapeutic targets in rheumatoid arthritis: the interleukin-6 receptor. Rheumatology 2010;49:15-24.
16. Atzeni F, Turiel M, Boccassini L, Sitia S, Tomasoni L, Battellino M, et al. Cardiovascular involvement in psoriatic arthritis [in Italian]. Reumatismo 2011;63:148-54.